DEF: Eyenovia Seeks Stockholder Approval for Reverse Stock Split and Equity Plan Amendment Amid Nasdaq Delisting Threat

Eyenovia is asking stockholders to approve a reverse stock split, an increase in shares for its incentive plan, and the potential issuance of shares upon warrant exercises, as it faces delisting from the Nasdaq.

Summary

• Eyenovia is holding a special virtual meeting on January 21, 2025, to seek stockholder approval for several key proposals.
• The company is proposing a reverse stock split of its common stock at a ratio between 1:40 and 1:80 to regain compliance with Nasdaq's minimum bid price requirement.
• Eyenovia also seeks to amend its 2018 Omnibus Stock Incentive Plan to reserve an additional 350,000 shares, which will not be adjusted for the reverse stock split.
• Additionally, the company is requesting approval for the potential issuance of up to 73,029,273 shares upon the exercise of purchase warrants issued in recent offerings.
• The board is also seeking authorization to adjourn the special meeting if necessary to solicit additional proxies if there are not sufficient votes in favor of the other proposals.
• The company received a delisting notice from Nasdaq after its stock price fell below $0.10 for 10 consecutive trading days, and is appealing the decision.
• As of December 9, 2024, there were 111,425,129 shares of common stock issued and outstanding.

Sentiment

Score: 4

Explanation: The document presents a mix of positive actions (reverse stock split, incentive plan amendment) and negative circumstances (delisting notice, financial uncertainty). The overall sentiment is cautiously negative due to the significant challenges the company is facing.

Positives

• The reverse stock split is intended to increase the share price, potentially attracting more investors and facilitating future financings.
• Maintaining the Nasdaq listing could provide a broader market for the company's stock.
• The additional shares for the incentive plan are intended to help attract and retain key personnel.
• The potential warrant exercises could bring in up to $10.84 million in additional capital.
• The company is taking steps to address the Nasdaq delisting notice by appealing the decision.

Negatives

• The company's stock price has fallen below Nasdaq's minimum bid price requirement, leading to a delisting notice.
• There is no guarantee that the reverse stock split will increase the stock price or maintain it above $1.00.
• The reverse stock split could lead to a loss of value if the share price does not rise proportionately.
• The potential issuance of a large number of shares upon warrant exercise could cause substantial dilution for existing shareholders.
• The company's limited liquidity raises substantial doubt about its ability to continue as a going concern.

Risks

• The reverse stock split may not result in a sustained increase in the per share price of the common stock.
• If the company is delisted from Nasdaq, it could be more difficult to sell shares and raise capital.
• The potential issuance of a large number of shares could depress the market price of the common stock.
• The company's ability to continue as a going concern is dependent on securing additional financing.
• There is a risk that the company may not be able to successfully commercialize its products.

Future Outlook

The company's future depends on regaining Nasdaq compliance, securing additional financing, and successfully commercializing its products. The reverse stock split is a key step in addressing the delisting notice, but there is no guarantee of success. The company is also exploring strategic alternatives.

Management Comments

• Michael M. Rowe, Chief Executive Officer and President, stated that the company believes hosting a virtual meeting enables greater stockholder attendance and participation.
• The Board believes that maintaining the Nasdaq listing may provide a broader market for the common stock and facilitate financing and other transactions.

Industry Context

The document reflects the challenges faced by small-cap biotech companies in maintaining stock prices and meeting listing requirements. The need for a reverse stock split and additional capital raises is not uncommon in this sector, especially for companies that are pre-revenue or in the early stages of commercialization. The company's situation highlights the importance of achieving clinical and regulatory milestones to drive investor confidence and stock value.

Comparison to Industry Standards

• Reverse stock splits are a common strategy for companies facing delisting from major exchanges, particularly in the biotech and pharmaceutical sectors where stock prices can be volatile and dependent on clinical trial results and regulatory approvals. For example, companies like Aeterna Zentaris and BioDelivery Sciences International have also recently undertaken reverse stock splits to maintain their Nasdaq listings.
• The proposed increase in shares for the stock incentive plan is also a standard practice for companies in the biotech industry to attract and retain talent. Companies like Amarin and Heron Therapeutics have similar stock-based compensation plans to incentivize employees and align their interests with shareholders.
• The potential issuance of shares upon warrant exercises is a common method for raising capital in the biotech industry, especially for companies that are not yet profitable. Companies like Cassava Sciences and Ocugen have used similar financing methods to fund their operations and clinical trials.
• The need for additional capital raises and the risk of dilution are also common challenges for biotech companies. Many companies in this sector rely on equity financing to fund their research and development activities, which can lead to dilution for existing shareholders. For example, companies like Sorrento Therapeutics and Inovio Pharmaceuticals have frequently raised capital through equity offerings, which has resulted in significant dilution for their shareholders.

Stakeholder Impact

• Shareholders face potential dilution from the issuance of new shares and the risk of further stock price decline.
• Employees may be affected by the company's financial instability and potential restructuring.
• The company's ability to continue operations and commercialize products could impact customers and suppliers.
• Creditors face increased risk due to the company's financial challenges.

Next Steps

• Stockholders will vote on the proposals at the special meeting on January 21, 2025.
• The board will decide whether to implement the reverse stock split if approved by stockholders.
• The company will continue to pursue its appeal of the Nasdaq delisting notice.
• The company will continue to explore strategic alternatives.

Key Dates

Keywords

reverse stock split, Nasdaq delisting, stock incentive plan, share issuance, purchase warrants, proxy statement, common stock, capital raise, stock options, equity dilution